Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 14
    records per page

    Dynamic Change of COVID-19 Seroprevalence SERO among Asymptomatic TRANS Population in Tokyo during the Second Wave

    Authors: Sawako Hibino; Kazutaka Hayashida; Andrew C Ahn; Yasutaka Hayashida; Julia Bielicki; Tim Roloff; Roland Bingisser; Christian Nickel; Nina Khanna; Sarah Tschudin; Andreas Widmer; Katharina Rentsch; Hans Pargger; Martin Siegemund; Daiana Stolz; Michael Tamm; Stefano Bassetti; Michael Osthoff; Manuel Battegay; Adrian Egli; Hans H Hirsch; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.21.20198796 Date: 2020-09-23 Source: medRxiv

    Importance: Fatality rates related to COVID-19 in Japan have been low compared to Western Countries and have decreased despite the absence of lockdown. Serological tests SERO monitored across the course of the second wave can provide insights into the population-level prevalence SERO and dynamic patterns of COVID-19 infection MESHD. Objective: To assess changes in COVID-19 seroprevalence SERO among asymptomatic TRANS employees working in Tokyo during the second wave. Design: We conducted an observational cohort study. Healthy volunteers working for a Japanese company in Tokyo were enrolled from disparate locations to determine seropositivity against COVID19 from May 26 to August 25, 2020. COVID-19 IgM and IgG antibodies SERO were determined by a rapid COVID19 IgM/IgG test kit using fingertip blood SERO. Across the company, tests were performed and acquired weekly. For each participant, serology tests were offered twice, separated by approximately a month, to provide self-reference of test results and to assess for seroconversion and seroreversion. Setting: Workplace setting within a large company. Participants: Healthy volunteers from 1877 employees of a large Japanese company were recruited to the study from 11 disparate locations across Tokyo. Participants having fever HP fever MESHD, cough HP cough MESHD, or shortness of breath MESHD at the time of testing were excluded. Main Outcome(s) and Measure(s): Seropositivity rate (SPR) was calculated by pooled data from each two-weeks window across the cohort. Either IgM or IgG positivity was defined as seropositive. Changes in immunological status against SARS-CoV-2 were determined by comparing results between two tests obtained from the same individual. Results: Six hundred fifteen healthy volunteers (mean + SD 40.8 + 10.0; range 19-69; 45.7 % female TRANS) received at least one test. Seroprevalence SERO increased from 5.8 % to 46.8 % over the course of the summer. The most dramatic increase in SPR occurred in late June and early July, paralleling the rise in daily confirmed cases TRANS within Tokyo, which peaked on August 4. Out of the 350 individuals (mean + SD 42.5 + 10.0; range 19-69; 46.0 % female TRANS) who completed both offered tests, 21.4 % of those individuals who tested seronegative became seropositive and seroreversion was found in 12.2 % of initially seropositive participants. 81.1% of IgM positive cases at first testing became IgM negative in approximately one month. Conclusions and Relevance: COVID-19 infection MESHD may have spread widely across the general population of Tokyo despite the very low fatality rate. Given the temporal correlation between the rise in seropositivity and the decrease in reported COVID-19 cases that occurred without a shut-down, herd immunity may be implicated. Sequential testing for serological SERO response against COVID-19 is useful for understanding the dynamics of COVID-19 infection at the population-level.

    Seroprevalence SERO of anti-SARS-CoV-2 IgG antibody SERO in hospitalized patients in a tertiary referral center in North India

    Authors: Animesh Ray; Komal Singh; Souvick Chattopadhyay; Farha Mehdi; Gaurav Batra; Aakansha Gupta; Ayush Agarwal; Bhavesh M; Shubham Sahni; Chaithra R; Shubham Agarwal; Chitrakshi Nagpal; Gagantej B H; Umang Arora; Kartikeya Kumar Sharma; Ranveer Singh Jadon; Ashish Datt Upadhyay; Neeraj Nischal; Naval K Vikram; Manish Soneja; R M Pandey; Naveet Wig; Alessandra C. Sanchez; Haifa L. Gaza; Geraldine M. Arevalo; Coleen M. Pangilinan; Shaira A. Acosta; Melanie V. Salinas; Brian E. Schwem; Angelo D. Dela Tonga; Ma. Jowina H. Galarion; Nina Theresa P. Dungca; Stessi G. Geganzo; Neil Andrew D. Bascos; Eva Maria Cutiongco-de la Paz; Cynthia P. Saloma; Alberto L Garcia-Basteiro

    doi:10.1101/2020.08.22.20179937 Date: 2020-08-25 Source: medRxiv

    Background: Seroprevalence SERO of IgG antibodies SERO against SARS-CoV-2 is an important tool to estimate the true extent of infection MESHD in a population. However, seroprevalence SERO studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases TRANS in the world. The present study aimed to estimate the seroprevalence SERO of the anti-SARS-CoV-2 IgG antibody SERO among hospitalized patients at one of the largest government hospital in India. Method: This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody SERO levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum samples SERO by the ELISA SERO method. Results: A total of 212 hospitalized patients were recruited in the study with mean age TRANS (+/-SD) of 41.2 (+/-15.4) years and 55% male TRANS population. Positive serology against SARS CoV-2 was detected in 19.8% patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p-value 0.001. No particular age groups TRANS or socio-economic strata showed a higher proportion of seropositivity. Conclusion: Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups TRANS and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21) Key Words: SARS-CoV-2 IgG Antibody SERO, Seroprevalence SERO, Hospitalized patient, COVID-19

    Antibody Testing SERO Documents the Silent Spread of SARS-CoV-2in New York Prior to the First Reported Case

    Authors: Kathrine Meyers; Lihong Liu; Wen-Hsuan Lin; Yang Luo; Michael Yin; Yumeng Wu; Sandeep Wontakal; Alex Rai; Francesca La Carpia; Sebastian Fernando; Mitra Dowlatshahi; Elad Elkayam; Ankur Garg; Leemor Joshua-Tor; John Wolk; Barbara Alpert; Marie-Laure Romney; Brianna Costabile; Edoardo Gelardi; Francesca Vallese; Oliver Clarke; Filippo Mancia; Anne-Catrin Uhlemann; Magdalena Sobieszczyk; Alan Perelson; Yaoxing Huang; Eldad Hod; David Ho

    doi:10.21203/ Date: 2020-07-02 Source: ResearchSquare

    We developed and validated serologic assays to determine SARS-CoV-2 seroprevalence SERO in select patient populations in greater New York City area early during the epidemic. We tested “discarded” serum samples SERO from February 24 to March 29 for antibodies SERO against SARS-CoV-2 spike trimer and nucleocapsid protein. Using known durations for antibody SERO development, incubation period TRANS, serial interval TRANS, and reproductive ratio for this pandemic, we determined that introduction of SARS-CoV-2 into New York likely occurred between January 23 and February 4, 2020. SARS-CoV-2 spread silently for 4–5 weeks before the first community acquired infection MESHD was reported. A novel coronavirus emerged in December 2019 in Wuhan, China1,2 and devasted Hubei Province in early 2020 before spreading to every province within China and nearly every country in the world3. This pathogen, now termed severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has caused a global pandemic, with ~ 10 million cases and over 500,000 deaths MESHD reported through June 30, 20203. The first case of SARS-CoV-2 infection MESHD in the United States was identified on January 19, 2020 in a man who returned to the State of Washington from Wuhan4. In the ensuing months, the U.S. has become a hotspot of the pandemic, presently accounting for almost one third of the total caseload and over one fourth of the deaths3. The first confirmed case TRANS in New York was reported on March 1 in a traveler recently returned from Iran. The first community-acquired SARS-CoV-2 infection MESHD was diagnosed on March 3 in a 50-year-old male TRANS who lived in New Rochelle and worked in New York City ( In the ensuing 18 weeks, New York City has suffered a peak daily infection number of ~ 4,500 (Fig. 1a) and a cumulative caseload of ~ 400,000 to date. The time period when SARS-CoV-2 gained entry into this epicenter of the pandemic remains unclear.

    Asymptomatic TRANS people with SARS-CoV-2 as unseen carriers TRANS of COVID-19: A systematic review and meta-analysis

    Authors: Gopiram Syangtan; Shrijana Bista; Prabin Dawadi; Binod Rayamajhee; Lok Bahadur Shrestha; Reshma Tuladhar; Dev Raj Joshi

    doi:10.21203/ Date: 2020-07-01 Source: ResearchSquare

    Background The asymptomatic TRANS patients with SARS-CoV-2 can act as an unseen carrier TRANS for magnifying the transmission TRANS of COVID-19.Aims This study was designed to appraise the burden of asymptomatic TRANS individuals and estimate their occurrence among different age groups TRANS and gender TRANS by reviewing the existing published data on asymptomatic TRANS people with COVID-19.Methods Three electronic databases: PubMed, Embase and Web of Science (WoS) were used to search studies as per the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and the search was limited to English language. The study population of this review includes asymptomatic TRANS individuals infected by COVID-19. All original articles which have reported cases of the COVID-19 patients with no symptoms until 31 April 2020 were included in the study. Random effects model was applied to analyze pooled data on the prevalence SERO of symptomless cases among total COVID-19 infected MESHD patients and also on different age groups TRANS and gender TRANS.Results In the meta-analysis of 16 studies, comprising 2,788 COVID-19 infected MESHD patients, the pooled prevalence SERO of asymptomatic TRANS cases was 48.2% (95% CI, 30%-67%). Among the asymptomatic TRANS patients, 55.5% (95% CI, 43.6%-66.8%) were female TRANS and 49.6% (95% CI, 20.5%-79.1%) were children TRANS.Conclusion About half of the COVID-19 infected MESHD patients were asymptomatic TRANS cases. Children TRANS and females TRANS were more apparent to be asymptomatic TRANS patient of COVID-19 and could act as unseen carrier TRANS of SARS-CoV-2. Symptom based screening only, might fail to identify all SARS-CoV-2 infections escalating MESHD the threat of global spread of SARS-CoV-2. Therefore, mass surveillance system tracking asymptomatic TRANS cases is a pressing need of public health, paying special attention to female TRANS and young children TRANS, which could aid in prevention and containment of this unprecedented pandemic.

    Novel coronavirus (COVID-19) Outbreak in Iraq: The First Wave and Future Scenario

    Authors: Adil R. Sarhan; Mohammed H. Flaih; Thaer A. Hussein; Khwam R. Hussein

    doi:10.1101/2020.06.23.20138370 Date: 2020-06-26 Source: medRxiv

    The first patient with COVID-19 was reported in Iraq on 24 February 2020 for the Iranian student came from Iran. As of 24 May 2020, the confirmed cases TRANS of COVID-19 infections reached 4469, with 160 deaths MESHD and 2738 patients were recovered from the infection MESHD. Significant public health strategies have been implemented by the authorities to contain the outbreak nationwide. Nevertheless however, the number of cases is still rising dramatically. Here, we aim to describe a comprehensive and epidemiological study of all cases diagnosed in Iraq by 24 May 2020. Most of the cases were recorded in Baghdad followed by Basra and Najaf. About 45% of the patients were female TRANS (with 31% deaths of the total cases) and 55% were male TRANS (with 68% deaths of the total cases). Most cases are between the ages TRANS of (20-59) years old, and (30-39) years are the most affected range (19%) Approximately (8%) of cases are children TRANS under 10 years old. Iraq has shown a cure rate lower than those reported by Iran, Turkey and Jordan; and higher than Saudi Arabia and Kuwait. Healthcare workers represented about (5%) of the total confirmed cases TRANS. These findings enable us to understand COVID-19 epidemiology and prevalence SERO in Iraq that can alert the our community to the risk of this novel coronavirus and serve as a baseline for future studies.

    Double COVID-19 Confirmed Case TRANS Fatality Rate in Countries with High Elderly TRANS Female TRANS Vitamin D Deficiency Prevalence SERO

    Authors: Alex Backer; Myron Mageswaran

    doi:10.1101/2020.06.13.20130484 Date: 2020-06-16 Source: medRxiv

    A number of clues point to a possible role of vitamin D in fighting COVID-19: a reduction in case growth speed with solar zenith angle, higher fatality rate in black people MESHD, lower fatality rate in populations that spend more time outdoors. Yet a direct demonstration that vitamin D deficiency MESHD is associated with COVID-19 fatalities has remained elusive. We show here in a comparison of 32 countries that countries with high prevalence SERO of vitamin D deficiency MESHD among elderly TRANS females TRANS show a confirmed case TRANS fatality rate twice as high as those with low prevalence SERO. We then show that this effect cannot be explained by differences in life expectancy between countries. A mechanistic role for vitamin D in the severity of COVID-19 is proposed.

    Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern with under-reporting of prevalence SERO and deaths

    Authors: Mahan Ghafari; Bardia Hejazi; Arman Karshenas; Stefan Dascalu; Luca Ferretti; Alice Ledda; Mohammad Ali Khosravi; Maryam Abbasalipour; Sirous Zeinali; Aris Katzourakis

    doi:10.21203/ Date: 2020-05-29 Source: ResearchSquare

    Iran was among the first group of countries with a major outbreak of COVID-19 in Asia. With nearly 100 exported cases to various other countries by Feb 25, 2020 it has since been the epicentre of the outbreak in the Middle East. By examining the age TRANS- and gender TRANS-stratified national data taken from PCR- confirmed cases TRANS and deaths related to COVID-19 on Mar 13 (reported by the Iranian ministry of health) and those taken from hospitalised patients in 14 university hospitals across Tehran on Apr 4 (reported by Tehran University of Medical Sciences), we find that the crude case fatality ratio of the two reports in those aged TRANS 60 and younger are identical and are almost 10 times higher than those reported from China, Italy, Spain and several other European countries (reported from government or ministry of health websites). Assuming a constant attack rate TRANS across all age-groups TRANS, we adjust for demography, delay from confirmation to death, and under-ascertainment of cases, to estimate the infection fatality ratio based on the reports from Mar 13. We find that our estimates are aligned with reports from China and the UK for those aged TRANS 60 and above [n=4609], but are 2-3 times higher in younger age-groups TRANS [n=6756] suggesting that only less than 10% of symptomatic cases were detected across the country at the time. Using inbound travel TRANS data (from China to Iran) and matching the dates of the flights with prevalence SERO of cases in China from Jan to Mar 2020, we assess the risk of importation of active cases into the country. Further, using outbound travel TRANS data, based on detected cases exported from Iran to several other countries, we estimate the size of the outbreak in the country on Feb 25 and Mar 6 to be 13,700 (95% CI: 7,600 - 33,300) and 60,500 (43,200 - 209,200), respectively. We next estimate the start of the outbreak using 18 whole-genome sequences obtained from cases with a travel TRANS history to Iran and the first sequence obtained from inside the country. Finally, we use a mathematical model to predict the evolution of the epidemic and assess its burden on the healthcare system. Our modelling analysis suggests the first peak of the epidemic was on Apr 5 and the next one likely follows within the next 6-10 weeks with approximately 30,000 ICU beds required (IQR: 12K - 60K) and over 1 million active cases (IQR: 740K - 3.7M) during the peak weeks. We caution that relaxed, stringent intervention measures, during a period of highly under-reported spread, would result in misinformed public health decisions and a significant burden on the hospitals in the coming weeks.

    Meta-regression of COVID-19 prevalence SERO/fatality on socioeconomic characteristics of data from top 50 U.S. large cities

    Authors: Hisato Takagi; Toshiki Kuno; Yujiro Yokoyama; Hiroki Ueyama; Takuya Matsushiro; Yosuke Hari; Tomo Ando

    doi:10.1101/2020.05.25.20112599 Date: 2020-05-27 Source: medRxiv

    To screen potential risk and protective socioeconomic factors for Coronavirus disease MESHD 2019 (COVID-19) prevalence SERO and fatality, meta-regression of data from top 50 U.S. large-population cities was performed. The population estimate (in 2019) of each country to which the city belongs was abstracted from the "County Population Totals: 2010-2019." From the "Johns Hopkins Coronavirus Resource Center," the cumulative number of confirmed cases TRANS and deaths of COVID-19 in each country was obtained on May 22, 2020. Socioeconomic characteristics of each country were extracted from the "2014-2018 American Community Survey (ACS) 5-Year Data Profile" and "Small Area Income and Poverty Estimates (SAIPE) Program (for 2018)." Radom-effects meta-regression was performed using OpenMetaAnalyst ( A coefficient (slope of the meta-regression line) for COVID-19 prevalence SERO was significantly negative for male TRANS sex, education attainment, computer and Internet use, and private health insurance. Whereas, the coefficient was significantly positive for black race, never matrimony, unemployment, and poverty. In the multivariable model, the coefficient was significantly negative for male TRANS sex (P = 0.036) and computer use (P = 0.024), and significantly positive for never matrimony (P < 0.001). A coefficient for COVID-19 fatality was significantly negative for no health insurance, and significantly positive for elderly TRANS, unemployment, and public coverage. In the multivariable model, the coefficient was significantly positive for only elderly TRANS (P = 0.002). In conclusion, a number of socioeconomic factors, e.g. male TRANS sex (negatively for prevalence SERO), elderly TRANS (positively for fatality), never matrimony (positively for prevalence SERO), and computer use (negatively for prevalence SERO) may be associated with COVID-19.

    Association of age TRANS, sex, comorbidities, and clinical symptoms with the severity and mortality of COVID-19 cases: a meta-analysis with 85 studies and 67299 cases

    Authors: Mohammad Safiqul Islam; Md. Abdul Barek; Md. Abdul Aziz; Tutun Das Aka; Md. Jakaria

    doi:10.1101/2020.05.23.20110965 Date: 2020-05-26 Source: medRxiv

    Background: A new pathogenic disease named COVID-19 became a global threat, first reported in Wuhan, China, in December 2019. The number of affected cases growing exponentially and now, more than 210 countries confirmed the cases TRANS. Objective: This meta-analysis aims to evaluate risk factors, the prevalence SERO of comorbidity, and clinical characteristics in COVID-19 death MESHD patients compared to survival patients that can be used as a reference for further research and clinical decisions. Methods: PubMed, Science Direct, SAGE were searched to collect data about demographic, clinical characteristics, and comorbidities of confirmed COVID-19 patients from January 1, 2020, to May 17, 2020. Meta-analysis was performed with the use of Review Manager 5.3 Results: Eighty-five studies were included in Meta-analysis, including a total number of 67,299 patients with SARS-CoV-2 infection MESHD. Males TRANS are severely affected or died than females TRANS (OR = 2.26, p < 0.00001; OR = 3.59, p < 0.00001) are severely affected, or died by COVID-19 and cases with age TRANS [≥]50 are at higher risk of death MESHD than age TRANS <50 years (OR=334.23). Presence of any comorbidity or comorbidities like hypertension HP hypertension MESHD, cardiovascular disease MESHD, diabetes MESHD, cerebrovascular disease MESHD, respiratory disease MESHD, kidney disease MESHD, liver disease MESHD, malignancy MESHD significantly increased the risk of death compared to survival (OR = 3.46, 3.16, 4.67, 2.45, 5.84, 2.68, 5.62, 2.81,2.16). Among the clinical characteristics such as fever HP fever MESHD, cough HP cough MESHD, myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, abdominal pain HP abdominal pain MESHD, dyspnea HP dyspnea MESHD, fatigue HP fatigue MESHD, sputum production, chest tightness HP chest tightness MESHD headache HP and nausea or vomiting HP nausea or vomiting MESHD, only fatigue HP fatigue MESHD (OR = 1.31, 95%) and dyspnea HP dyspnea MESHD increased the death significantly (OR= 1.31, 4.57). The rate of death of COVID-19 cases is 0.03-times lower than the rate of survival (OR = 0.03). Conclusion Our result indicates that male TRANS patients are affected severely or died, the rate of death is more in the age TRANS [≥]50 group, and the rate of death is affected by comorbidities and clinical symptoms.

    Risk factors affecting COVID-19 case fatality rate: A quantitative analysis of top 50 affected countries

    Authors: Hui Poh Goh; Wafiah Ilyani Mahari; Norhadyrah Izazie Ahad; Liling Chaw; Nurolaini Kifli; Bey Hing Goh; Siang Fei Yeoh; Long Chiau Ming

    doi:10.1101/2020.05.20.20108449 Date: 2020-05-25 Source: medRxiv

    Background: Latest clinical data on treatment on coronavirus disease MESHD 2019 (COVID-19) indicated that older patients and those with underlying history of smoking, hypertension HP hypertension MESHD or diabetes mellitus HP diabetes mellitus MESHD might have poorer prognosis of recovery from COVID-19. We aimed to examine the relationship of various prevailing population-based risk factors in comparison with mortality rate and case fatality rate (CFR) of COVID-19. Methods: Demography and epidemiology data which have been identified as verified or postulated risk factors for mortality of adult TRANS inpatients with COVID-19 were used. The number of confirmed cases TRANS and the number of deaths until April 16, 2020 for all affected countries were extracted from Johns Hopkins University COVID-19 websites. Datasets for indicators that are fitting with the factors of COVID-19 mortality were extracted from the World Bank database. Out of about 185 affected countries, only top 50 countries were selected to be analyzed in this study. The following seven variables were included in the analysis, based on data availability and completeness: 1) proportion of people aged TRANS 65 above, 2) proportion of male TRANS in the population, 3) diabetes MESHD prevalence SERO, 4) smoking prevalence SERO, 5) current health expenditure, 6) number of hospital beds and 7) number of nurses and midwives. Quantitative analysis was carried out to determine the correlation between CFR and the aforementioned risk factors. Results: United States shows about 0.20% of confirmed cases TRANS in its country and it has about 4.85% of CFR. Luxembourg shows the highest percentage of confirmed cases TRANS of 0.55% but a low 2.05% of CFR, showing that a high percentage of confirmed cases TRANS does not necessarily lead to high CFR. There is a significant correlation between CFR, people aged TRANS 65 and above (p = 0.35) and diabetes MESHD prevalence SERO (p = 0.01). However, in our study, there is no significant correlation between CFR of COVID-19, male TRANS gender TRANS (p = 0.26) and smoking prevalence SERO (p = 0.60). Conclusion: Older people above 65 years old and diabetic MESHD patients are significant risk factors for COVID-19. Nevertheless, gender TRANS differences and smoking prevalence SERO failed to prove a significant relationship with COVID-19 mortality rate and CFR. Keywords: Coronavirus, COVID-19, risk, epidemiology, fatality, age TRANS, diabetes MESHD

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.